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Abstract
Background: Tick-borne relapsing fevers of humans are caused by spirochetes that must adapt to both warm-blooded
vertebrates and cold-blooded ticks. In western North America, most human cases of relapsing fever are caused
by Borrelia hermsii, which cycles in nature between its tick vector Ornithodoros hermsi and small mammals such as
tree squirrels and chipmunks. These spirochetes alter their outer surface by switching off one of the bloodstream-
associated variable major proteins (Vmps) they produce in mammals, and replacing it with the variable tick protein
(Vtp) following their acquisition by ticks. Based on this reversion to Vtp in ticks, we produced experimental vaccines
comprised on this protein and tested them in mice challenged by infected ticks.
Methods: The vtp gene from two isolates of B. hermsii that encoded antigenically distinct types of proteins were
cloned, expressed, and the recombinant Vtp proteins were purified and used to vaccinate mice. Ornithodoros hermsi
ticks that were infected with one of the two strains of B. hermsii from which the vtp gene originated were used to
challenge mice that received one of the two Vtp vaccines or only adjuvant. Mice were then followed for infection and
seroconversion.
Results: The Vtp vaccines produced protective immune responses in mice challenged with O. hermsi ticks infected
with B. hermsii. However, polymorphism in Vtp resulted in mice being protected only from the spirochete strain that
produced the same Vtp used in the vaccine; mice challenged with spirochetes producing the antigenically different
Vtp than the vaccine succumbed to infection.
Conclusions: We demonstrate that by having knowledge of the phenotypic changes made by B. hermsii as the
spirochetes are acquired by ticks from infected mammals, an effective vaccine was developed that protected mice
when challenged with infected ticks. However, the Vtp vaccines only protected mice from infection when challenged
with that strain producing the identical Vtp. A vaccine containing multiple Vtp types may have promise as an oral
vaccine for wild mammals if applied to geographic settings such as small islands where the mammal diversity is low
and the Vtp types in the B. hermsii population are defined.
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Background
The ability of some blood-borne pathogens to temporar-
ily evade their host’s immune system increases the
potential for these organisms to be horizontally trans-
ferred between susceptible individuals via the bite of
hematophagous arthropods [1]. Such is the case with
spirochetes that cause relapsing fever in humans, exem-
plified and best understood for Borrelia hermsii, the pri-
mary cause of tick-borne relapsing fever in western
North America [2]. This species of bacterium is main-
tained in enzootic cycles that include rodent hosts and
the argasid (soft) tick vector, Ornithodoros hermsi [3, 4].
People are accidental hosts when bitten by infected ticks
while sleeping in infested cabins or when disrupting
tick-infested debris [5–7].
Borrelia hermsii has the molecular machinery to vary
antigenically [8–10]. A single organism contains the gen-
etic potential to produce 60 or more antigenic variants,
which allow the spirochetes to evade the host’s humoral
immune response and sequentially produce a series of
serotype-specific populations that are antigenically dis-
tinct from one another [8, 11]. These cyclic and repeated
high cell densities (spirochetemias) of B. hermsii in a
wild rodent’s blood increase the opportunity for these
bacteria to be acquired by the fast-feeding ticks [12].
When humans become infected, these recurrent peaks
of spirochetemia are associated with repeated episodes
of acute illness, hence the name relapsing fever [13].
The large repertoire of antigenically distinct variable
major proteins (Vmps) that B. hermsii produces on its
cell surface when in the mammalian bloodstream has
complicated strategies to develop sensitive and specific
serological tests as well as vaccines [14]. Advancing the
former need, the periplasmic enzyme glycerophospho-
diester phosphodiesterase (GlpQ) in relapsing fever spi-
rochetes is highly immunogenic and conserved among
isolates; however, this protein does not produce a pro-
tective immune response [15–17]. Therefore, we tested
another protein that B. hermsii produces, not while cir-
culating in the bloodstream, but rather during infection
in its tick vector.
When B. hermsii is acquired by O. hermsi during its
blood meal, the spirochetes first accumulate in the tick’s
midgut and subsequently establish persistent infections
in the salivary glands and other tissues [18]. In the saliv-
ary glands, the spirochetes no longer produce the Vmp
that was made in the bloodstream at the time of ac-
quisition, but rather the spirochetes switch to making
a different surface protein called the variable tick pro-
tein (Vtp) [18–21]. This protein is paralogous to the
family of variable small proteins (Vsps) (a subset of
the Vmps) that B. hermsii produces during infection in
the blood [22]. However, there is only one copy of vtp
in the B. hermsii genome [20, 23], and this gene is
expressed by a different promoter than that by which
the vmps are expressed [23]. Therefore, within a given
clonal population or infectious lineage of B. hermsii,
Vtp does not vary.
We hypothesized that immunization with Vtp would
stimulate a protective antibody response against tick-
transmitted B. hermsii, as does the orthologous protein,
outer surface protein (Osp) C, that is produced by the
Lyme disease spirochete, Borrelia burgdorferi, when this
bacterium is transmitted by the hard tick Ixodes scapu-
laris [24–28]. Like OspC in B. burgdorferi [29], Vtp in B.
hermsii is polymorphic, and has seven antigenic types
described to date, and the synthesis of this protein is es-
sential for mammalian infection during transmission by
tick bite [21, 30]. Therefore, we cloned and expressed
the vtp gene from two strains of B. hermsii that pro-
duced different antigenic types of Vtp, immunized mice
with the purified proteins, and challenged the mice with
B. hermsii via the bite of infected O. hermsi ticks. Herein
we demonstrate that immunization with Vtp produced a
protective antibody response when the vaccinated ani-
mals were challenged with B. hermsii that produced the
same Vtp, but not when challenged with a strain that
produced a different antigenic type.
Methods
Bacterial isolates and cultivation
Borrelia hermsii isolates originated from diagnostic
samples from relapsing fever patients infected in eastern
Washington State (DAH) and western Montana (LAK-3).
These isolates represent the two genomic groups (GG) de-
scribed previously for B. hermsii [20, 30]. DAH is a mem-
ber of GGI and LAK-3 is a member of GGII. DAH
contains a vtp Type 6 gene while LAK-3 contains a vtp
Type 5 gene, and the two encoded proteins excluding the
signal peptide share 69.9 % amino acid identity. An iso-
genic mutant of B. hermsii DAH lacking Vtp was included
in some of the experiments [21, 31]. Borrelia hermsii cul-
tures were grown at 34 °C in BSK-II [32] or BSK-H
medium (Sigma-Aldrich Corp., St. Louis, MO) supple-
mented with 12 % rabbit serum.
Production of rabbit anti-Vtp antibody
Proteins in a whole-cell lysate of B. hermsii DAH pas-
sage 100 were separated by SDS-PAGE using a 17.5 %
polyacrylamide gel and a preparative comb with a 14-cm
continuous well. After electrophoresis, the unfixed gel
was stained with water-based Coomassie Brilliant Blue
lacking acetic acid, destained in water, and the domin-
ant ~20-kDa band (Vtp) was excised with a razor blade
from the gel in a 3-mm wide strip. One half of the gel
strip was triturated with a sterile mortar and pestle in
PBS and emulsified in an equal volume of Complete
Freund’s Adjuvant while the other half of the gel was
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frozen at −80 °C and kept for the booster immunization.
The primary immunization of the adult New Zealand
white rabbit (Oryctolagus cuniculus) totaled 2 ml delivered
by injection in four 0.5 ml doses, two intramuscularly in
each of the hind legs and two subcutaneously in the nape
of the neck. The rabbit received four booster shots 36 days
later following the same protocol except that the gel was
emulsified in Incomplete Freund’s Adjuvant. Immune
serum was collected from the rabbit 35 days later.
Production of recombinant Vtp
Total genomic DNA preparations from the two B. herm-
sii isolates were used as templates for PCR amplification
of the vtp gene. The forward and reverse primers used
to amplify the gene from both samples were 5’-TATCAT
ATGAATAATGGAGGCCCAG-3’ and 5’-CTCGAGTC
AAGG TTTAACAGGG-3’, respectively. These primers
lacked the first 57 nucleotides to exclude the 19 amino
acid signal peptide to optimize the heterologous syn-
thesis of the protein in Escherichia coli, as Carter
et al. reported that all attempts to clone the entire vtp
(= vmp33) gene into an expression vector failed [22].
PCR amplification was performed with the GoTaq
Flexi DNA polymerase kit (Promega, Madison, WI)
and the DNA Engine Tetrad (Bio-Rad Laboratories,
Inc., Hercules, CA). The amplification parameters in-
cluded an initial heating at 96 °C for 5 min, followed
by 35 cycles with a denaturing temperature of 94 °C
for 30 s, an annealing temperature of 58 °C for 30 s,
and an extension temperature of 72 °C for 2.5 min. Ampli-
cons were first inserted into the pCR2.1-TOPO TA vector
(Invitrogen/Life Technologies, Grand Island, NY) accord-
ing to manufacturer’s instructions, and the recombinant
plasmid was transformed into TOP10 electrocompetent E.
coli cells (Invitrogen/Life Technologies). Plasmid DNA
was purified with a Miniprep Kit (Qiagen, Valencia, CA)
and sequenced as previously described [20],which demon-
strated that no changes had been introduced in the genes.
The plasmids containing the DAH and LAK-3vtp
genes and the pET15b expression plasmid (Novagen,
Darmstadt, Germany) were digested for 2 h at 37 °C
with NdeI and XhoI (New England Biolabs, Ipswich,
MA). The vtp-containing fragments were gel-purified
and ligated into pET15b with an overnight incubation at
15 °C, and the ligation products were electroporated into
E. coli BL21 Star DE3 cells. The transformants were
plated on Luria-Bertani agar plates containing carbeni-
cillin (100 μg/ml) and single clones were screened by
PCR. Positive clones were grown in Luria-Bertani broth
containing carbenicillin (100 μg/ml) and expression was
induced with 1 mM IPTG (isopropyl-β-D-thiogalactopy-
ranoside) for 5 h at 37 °C. The E. coli lysates were exam-
ined by SDS-PAGE and immunoblots for the presence
of a HIS-tagged fusion protein of the expected size.
Membrane-bound proteins were probed with anti-
polyhistidine horseradish peroxidase-conjugated antibody
(Sigma-Aldrich Corp.) diluted 1:2,000. The proteins were
purified with a Ni-NTA His-Bind resin column (Novagen)
with 6 M urea-denaturing conditions, and then dialyzed in
a 10 K MWCO Slide-A-Lyzer cassette (Thermo Scientific,
Rockford, IL) to remove the urea. Protein concentrations
were determined using the colorimetric Bio-Rad Protein
Assay (Bio-Rad Laboratories) following the manufacturer’s
instructions.
Immunizations with rVtp
RML mice (Mus musculus) used in this study are an out-
bred strain that originated from the Swiss-Webster back-
ground and are bred at the Rocky Mountain Laboratories
(RML). Groups of five adult mice, 6 – 8 weeks old, re-
ceived their primary immunization by intraperitoneal in-
jection that included 200 pmol of purified rVtp protein
(4.45 or 4.48 μg of Vtp Type 5 and 6, respectively). Our
vaccine doses (~4.5 μg) were within the range of most
other recombinant protein vaccines (1 – 20 μg) used ex-
perimentally for rodents and Lyme disease spirochetes
[26, 33–36]. The purified proteins were suspended in
200 μl phosphate buffered saline (PBS) and mixed with
200 μl of the MPL + TDM+CWS Adjuvant System
M6661 (Sigma-Aldrich Corp.). The mice received two
identical booster immunizations 28 and 56 days later. Five
negative control mice for each experiment were also sham
immunized and boosted twice on the same schedule with
only 200 μl of adjuvant mixed with 200 μl of PBS.
Agglutination and borreliacidal assays
Serum from the immunized rabbit was tested for its
ability to agglutinate B. hermsii DAH cells. In a sterile
96-well flat-bottom tissue culture plate, 100 μl of serial
two-fold dilutions of immune and normal rabbit serum
were mixed with 100 μl of a stationary-phase (~108 spi-
rochetes/ml), high passage spirochete culture. The final
serum dilutions of the suspensions were 1:16 – 1:2048,
and the mixtures were incubated for 5 h at 37 °C and
then kept at RT overnight. The following morning, the
wells were examined with aninverted Nikon Diaphot
Phase Contrast microscope (Nikon Instruments Inc.,
Melville, NY) to assess the presence of agglutinated
spirochetes.
Serum from the Vtp-immunized rabbit was tested for
borreliacidal activity along with serum from a normal
non-immunized rabbit. The first assay tested the im-
mune and control sera at a 1:2 dilution by mixing 100 μl
of a stationary-phase (~108 spirochetes/ml), high passage
culture of B. hermsii DAH with 100 μl of the undiluted
immune or control serum, incubating the mixtures at
37 °C for 6 h, transferring the 200 μl into tubes contain-
ing 9 ml of BSK-II medium, and incubating the cultures
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for 9 days at 34 °C. In a second experiment, one ml of a
stationary-phase, high passage, Vtp-positive culture of B.
hermsii DAH was mixed with 1 ml of either the immune
or control serum in a sterile culture tube and placed at
37 °C. Starting 30 min later, and then every 30 min until
240 min had elapsed, 100 μl of each spirochete-serum
mixture was transferred to a tube containing 9 ml of
BSK-II medium. These 16 closed tubes were incubated
at 34 °C and examined on days 3 and 24 for the presence
of live spirochetes.
Serum samples from the immunized mice were tested
for their ability to agglutinate and kill B. hermsii. Ini-
tially, 100 μl of a stationary phase spirochete culture was
mixed with 100 μl of two-fold serial dilutions of serum
(1:16 to 1:2048) collected from mice just prior to their
challenge with infected ticks. These mixtures were incu-
bated for one hr at 37 °C, kept overnight at RT, and ex-
amined with an inverted Nikon Diaphot Phase Contrast
microscope.
To test viability, 50 μl of the overnight serum-
spirochete suspension was mixed with 150 μl of fresh
BSK-H and incubated for 7 h at 37 °C. From this mix-
ture, 5 μl was imaged as a wet preparation slide by dark-
field microscopy. These tests were repeated with serum
heated to 56 °C for 30 min to inactivate complement.
Challenge of immunized mice with B. hermsii-infected
ticks
The O. hermsi SIS ticks used for these studies came
from an uninfected colony maintained at the RML and
originated from a single pair of uninfected adults col-
lected from Siskiyou County, California [12]. Two co-
horts of nymphal ticks were first infected with either B.
hermsii DAH (that produced Vtp6) or B. hermsii LAK-3
(that produced Vtp5). The ticks were infected by feeding
them on a spirochetemic mouse that had been inocu-
lated intraperitoneally 3 – 4 days previously with a
BSK-H culture that contained one of the two strains of
spirochetes. Immediately after feeding, three ticks from
each group were dissected and the engorged midgut
from each tick was mixed in a drop of PBS and exam-
ined with a dark-field microscope. Spirochetes were
easily observed in all ticks examined, which confirmed
that the ticks became infected while feeding. After the
acquisition feeding, the engorged nymphal ticks were
kept at 21 °C and 85 % RH until they molted to their
next developmental stage. For challenge, groups of 5 in-
fected ticks were placed on each experimental animal
to allow them to feed. During tick feedings, the mice
were anesthetized by intraperitoneal injection of pento-
barbital sodium (0.5 mg/10 g body weight) (Abbott
Laboratories, North Chicago, IL).
Mice immunized with DAH rVtp (Type 6) or LAK-3
rVtp (Type 5) were challenged 23 and 24 days,
respectively, after receiving their second boost. Nearly
all the ticks fed during the challenge experiments. On 27
of the 30 mice, all 5 ticks attached; on one mouse, 4 of
the 5 ticks attached; on two mice, 3 of the 5 ticks at-
tached. Each mouse was checked daily on days 3 to 10
after tick feeding for spirochete infection by examining
blood collected from the tail vein [17]. Mice were anes-
thetized with isoflurane (Fluriso) (Vet ONE, MWI Veter-
inary Supply, Boise ID), the tip of the tail was nicked
with small surgical scissors, and a ~ 5 μl drop of blood
was expressed onto a glass microscope slide. The drop
was covered with a 22 mm x 22 mm cover slip and ex-
amined with a Nikon Eclipse E600 dark-field microscope
and 400X dry lens (Nikon Instruments Inc.). Once an
animal was found to be spirochetemic, the mouse was
scored as infected and not examined again. Following
tick challenge, the mice were held for an additional
60 days at which time terminal blood samples were col-
lected for serological analysis.
Serology
SDS-PAGE and immunoblots were performed as previ-
ously described [21]. Pre- and post-immunization serum
samples from the rabbit immunized with the gel-excised
Vtp were tested at 1:5000 dilutions with whole-cell ly-
sates of the wild-type B. hermsii DAH and the isogenic
deletion mutant lacking Vtp. The Vtp Type 6 specific
mAb H4825 [20, 37] was also tested with the same ly-
sates at 1:100 dilution to confirm the specificity of the
rabbit immune serum.
Mouse serum samples were collected prior to
immunization (pre-bleed), 20 days after the second boost
just prior to challenge (post-immunization), and 60 days
after challenge by tick-bite (post-challenge). These sam-
ples were tested for antibody reactivity by immunoblot
analysis and ELISA. Immunoblots included the two puri-
fied rVtps and B. hermsii DAH and LAK-3 whole-cell ly-
sates in the panel of antigens. The serum samples were
tested at 1:1,000 dilutions in PBS with 0.5 % Tween-20,
0.2 % weight/volume I-block (Applied Biosystems, Foster
City, CA). Bound antibodies were detected with the ex-
posure of film using Rec- protein A-HRP (1:4,000) and the
ECL Chemiluminescent Substrate Kit (Invitrogen).
Serological analyses by ELISA were done as described
previously [38]. Briefly, 20 ml cultures of B. hermsii DAH
and LAK-3 were grown to stationary phase (~108/ml), the
cells were centrifuged (12,500 x g), rinsed twice in PBS,
and suspended to an OD600 of 0.05. These cell suspen-
sions were sonicated and the whole-cell lysates were used
as antigen for analysis. Preliminary assays were done to as-
sess the level of antibody reactivity in the sera from the
different groups of mice collected at different time points,
and the assays were refined to better assess the end-point
titers. The samples were tested with the homologous and
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heterologous antigen strains. The post-immunization sam-
ples were tested at two-fold serial dilutions from 1:32,000
to 1:512,000 with the homologous strain and at three-fold
serial dilutions from 1:200 to 1:128,000 with the heterol-
ogous strain. Serum samples from the negative control
mice that received only the adjuvant and PBS were tested
at two-fold serial dilutions from 1:200 to 1:3,200. The pre-
bleed samples were used to determine the cutoff threshold
for positive samples by using their mean + 3 SD of the op-
tical density. The secondary detection antibody was
peroxidase-labeled goat anti-mouse IgG (H + L chain) di-
luted 1:5,000 (Kirkegaard and Perry Laboratories, Inc.,
Gaithersburg, MD). The reciprocal titers were trans-
formed with the log base 2, and the geometric mean titers
were calculated for each group and compared with one-
way ANOVA.
Indirect Fluorescent Antibody (IFA) staining of spirochete-
infected tick tissues
Salivary glands were dissected from ticks infected with
one of the two strains of spirochetes, squashed on glass
microscope coverslips, dried over an open flame and
then fixed in acetone. These samples were incubated
with one of two Vtp-specific monoclonal antibodies,
H4825 for the DAH Vtp (Type 6) [37] or H3548 for the
LAK-3 Vtp (Type 5) [20] as undiluted supernatants for
30 min, rinsed in PBS, and incubated with goat anti-
mouse-FITC conjugated antibody (1:100 dilution)
(Kirkegaard & Perry Laboratories) for 30 min. Some
preparations were stained with the rabbit polyclonal
anti-Vtp antibody described herein. The coverslips
were rinsed, dried, mounted with glycerol on glass
microscope slides and examined with a Nikon Eclipse
E800 epifluorescence microscope (Nikon Instruments
Inc.).
Ethics statement
The Rocky Mountain Laboratories, NIAID, NIH, Animal
Care and Use Committee approved study protocols for
the feeding of ticks on mice, mouse immunization and
infection of relapsing fever spirochetes (#2011-049), and
the immunization of rabbits (#93-10.54). All work was
conducted adhering to the institution’s guidelines for
animal husbandry, and followed the guidelines and basic
principals in the Public Health Service Policy on
Humane Care and Use of Laboratory Animals, and the
Guide for the Care and Use of Laboratory Animals,
United States Institute of Laboratory Animal Resources,
National Research Council.
Results
Rabbit immune serum is specific for Vtp
The rabbit immunized with the excised gel fragment
containing the ~20 kDa protein seroconverted to Vtp.
The specificity was demonstrated by immunoblot
when the pre- and post-immunization serum samples
were tested with B. hermsii lysates of strains contain-
ing and lacking Vtp (Fig. 1). The rabbit immune serum
and Vtp-specific monoclonal antibody recognized the
same protein in the wild-type B. hermsii but nothing
in the deletion mutant lacking Vtp. These results
demonstrated that the rabbit immune serum was spe-
cific for Vtp.
Fig. 1 Coomassie-stained gel (a) and immunoblots showing the seroconversion and specificity of the immune rabbit serum to Vtp (b, c), and the
recognition of Vtp Type 6 with the specific monoclonal antibody H4825 (d). Vtp- = B. hermsii mutant lacking Vtp; WT = wild type DAH producing
Vtp; MAb =monoclonal antibody. Molecular mass standards on left in kDa. * Identifies Vtp (a)
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Rabbit anti-Vtp immune serum agglutinates and kills
spirochetes
The rabbit immune serum agglutinated B. hermsii DAH
cells at dilutions of 1:16 –1:512 (Table 1). The pattern of
clumping varied from a continuous lattice at the lowest di-
lutions to significant, isolated clumps of cells at the middle
dilutions, to no longer being detectable at the two most
diluted samples (data not shown). No agglutination was
observed in any of the dilution wells containing serum
from the non-immunized rabbit.
Serum samples from the immunized and non-
immunized rabbits were tested for their ability to kill B.
hermsii. In the first assay with spirochetes exposed at a
1:2 serum dilution for 6 h at 37 °C, no spirochetes ex-
posed to the immune serum grew when transferred into
fresh BSK-II medium. In contrast, spirochetes mixed
with the serum from the non-immunized rabbit grew to
a high cell density in fresh medium. The second experi-
ment with spirochetes exposed to immune or non-
immune rabbit serum for 30–240 min also demon-
strated that no spirochetes grew when exposed to the
immune serum for as little as 30 min and then trans-
ferred to fresh medium. However, all cultures of spiro-
chetes exposed to serum from the non-immunized
rabbit grew out to high cell densities (data not shown).
These initial results demonstrated that the anti-Vtp
immune serum produced in the rabbit agglutinated and
killed spirochetes, which led us to produce
recombinant Vtps for use as experimental vaccines
against B. hermsii.
Immunized mice seroconvert to B. hermsii rVtp
All mice immunized with three injections of purified
rVtphad IgG antibody titers greater than or equal to
1:512,000 when tested by ELISA with the B. hermsii
isolate producing the homologous Vtp (Table 2). Anti-
body titers to the heterologous strain were much
lower and ranged from 1:200 up to 1:128,000 for two
samples, but demonstrated varying degrees of cross-
reactivity. All 10 mice immunized with only the adju-
vant were either non-reactive (<1:200) or reactive at
the lowest three dilutions. The same serum samples
from the immunized mice demonstrated a strong anti-
body response by immunoblot analysis to the purified
rVtp (Fig. 2).
Mouse immune serum to rVtp6 agglutinates and kills
spirochetes
Serum samples from mice immunized with rVtps or the
adjuvant were tested for their ability to agglutinate and
kill spirochetes. Serum from those mice immunized with
DAH rVtp (Type 6) produced large opaque clumps of
agglutinated B. hermsii DAH cells at 1:16 to 1:512 dilu-
tions (Fig. 3d, e, f ), whereas the serum from the
heterologous-immunized and control mice did not. Un-
expectedly, the immune serum from those mice immu-
nized with LAK-3 rVtp (Type 5) failed to agglutinate B.
hermsii LAK-3 cells. Additionally, serum from those
mice immunized with DAH rVtp (Type 6) killed B.
hermsii DAH spirochetes when diluted out to 1:128
(Table 3), which also happened with serum samples
heated to inactivate complement. But serum from mice
immunized with LAK-3 rVtp (Type 5) showed no borre-
liacidal activity when tested with B. hermsii LAK-3 (data
not shown). We examined a lysate of the freshly grown
LAK-3 strain and found that the culture had not entirely
switched to producing Vtp, but rather was still making
one of the variable large proteins (Vlps) that we did not
attempt to identify. We continued to cultivate these spi-
rochetes for two months, yet the population still failed
to switch to only making Vtp. Therefore, we abandoned
this part of the work and concluded that the immune
serum produced to rVtp5 failed to agglutinate and kill
spirochetes in vitro because the majority of the popula-
tion of spirochetes used in the assay was not producing
the target Vtp.
Mice immunized with rVtp are protected from infection
when challenged by tick bite
Cohorts of O. hermsi ticks infected with B. hermsii DAH
or LAK-3 were fed on mice immunized with rVtp6,
rVtp5, or only the adjuvant to assess the efficacy of the
two vaccines. All mice immunized with rVtp6 or rVtp5
were protected when fed upon by ticks infected with the
strain producing the same Vtp (Table 4), as no spiro-
chetes were detected for up to10 days following chal-
lenge. In contrast, immunization with the rVtps failed to
protect mice from infection when challenged by ticks in-
fected with the strain of B. hermsii producing the heter-
ologous Vtp type. Also, none of the 10 mice that
received only the adjuvant were protected and became
spirochetemic by day-3 post challenge (Table 4). During
Table 1 Agglutination of Borrelia hermsii DAH with rabbit anti-Vtp immune serum
Dilution of serum tested
Serum 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048
Rabbit anti-Vtp6 + + + + + + - -
Rabbit Neg. control - - - - - - - -
+, agglutination;-,no agglutination
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the heterologous challenges, one of the five mice immu-
nized with rVtp6 failed to become spirochetemic after
the first feeding of ticks infected with B. hermsii LAK-3.
This mouse was challenged again 28 days later with 5
LAK-3 infected ticks, which resulted in infection with a
detectable spirochetemia four days later.
Serum samples collected from the mice 60 days after
being fed upon by infected ticks (post challenge) were
tested by immunoblot with whole-cell lysates of the
homologous strain. Those animals immunized with rVtp
and challenged with the homologous strain (mice pro-
tected from infection) produced antibodies only to the
native Vtp (the vaccine) (Fig. 4b, f ). In contrast, serum
samples from animals challenged with the heterologous
strain(Fig. 4c, e), and those mice that received only the
adjuvant (Fig. 4a, d), showed reactivity to multiple pro-
teins demonstrating seroconversion as a result of infec-
tion, although the strength and diversity of the
responses varied among the groups. Together, both the
monitoring of spirochetemia and the serological analysis
demonstrated that immunization with rVtp conferred
protection from B. hermsii infection when the vacci-
nated mice were fed upon by infected ticks harboring
the strain producing the identical Vtp but not with a Vtp
of an antigenically different type.
Demonstration of spirochetes in ticks used to challenge
vaccinated mice
None of the 10 immunized mice that were challenged
with B. hermsii producing the homologous Vtp became
infected. To exclude the possibility that this result might
be due to the challenge ticks not being infected, we fed
the surviving members of each tick group again two
months later on non-immunized mice. Nine of the 10
original tick groups (4 of the 5 groups infected with
DAH; all 5 groups infected with LAK-3) had 2 – 5 sur-
viving ticks, and when each group was fed on a non-
immunized mouse, all 9 animals became infected with a
detectable spirochetemia 3–4 days later.
Additionally, three ticks from one group infected with
DAH and one group infected with LAK-3 were exam-
ined microscopically for infection after feeding first on
Table 2 ELISA titers in mice immunized with rVtp5, rVtp6 or
only adjuvant when tested with Borrelia hermsii whole-cell
lysates DAH or LAK-3
Tested with DAH whole-cell lysate
Vaccine Number of Mice Titers*
Adjuvant only (N = 5) all <1:200
Vtp6 (DAH) (N = 5) all≥ 1:512,000
Vtp5 (LAK-3) (N = 5) 1:200; 3 @ 1:5.400; ≥ 1:16,200
Tested to LAK-3 whole-cell lysate
Vaccine Number of Mice Titers**
Adjuvant only (N = 5) 2 @ < 1:200; 1:200; 1:400; 1:800
Vtp6 (DAH) (N = 5) 1:16,000; 2 @ 1:64,000; 2 @ 1:128,000
Vtp5 (LAK-3) (N = 5) all≥ 1:512,000
Geometric mean titers of each group significantly different, *p = 0.0008;
**p = 0.0001
Fig. 2 Immunoblot analysis of serum from mice immunized with
only the adjuvant (a) or purified recombinant Vtp 6 with adjuvant
(b). Antigen was purified Vtp 6 and serum samples were tested at
1:200 dilutions. Five mice were examined in each group (M1 – M5).
Molecular mass standards on left in kDa. Arrow indicates the primary
Vtp protein, slightly larger than the native protein because of the
6-histidine tag; larger aggregates of the protein are above
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the vaccinated mice and then on the non-immunized
mice. IFA stains were performed on the tick salivary
glands using monoclonal antibodies specific for each
Vtp. All six ticks were infected and contained spiro-
chetes in the salivary glands that were Vtp-positive
(Fig. 5a). Thus the lack of infection in those immunized
mice fed upon by ticks infected with B. hermsii produ-
cing the homologous Vtp was not due to the challenge
ticks being uninfected, but rather through the
protection afforded by the vaccination. As expected, in-
fected ticks that fed on the control mice that were im-
munized with only the adjuvant also contained
spirochetes in the salivary glands that produced Vtp
(Fig. 5b).
Fig. 3 Agglutination assays with mouse immune sera and B. hermsii DAH cells producing Vtp Type 6. Serum from mice immunized with rVtp
Type 6 caused significant aggregation of spirochetes (d, e, f) not observed with the serum from the mice immunized with only the adjuvant
(a, b, c) or the heterologous rVtp Type 5 (g, h, i). Serum dilutions are shown on the top and the type of immune serum is shown on the left
Table 3 Killing activity of mouse immune serum to Borrelia
hermsii DAH (Vtp6)
Dilution of serum tested
Serum 1:16 1:32 1:64 1:128 1:256 1:512 1:1024 1:2048
Mouse anti-Vtp6 - - - - + + + +
Mouse anti-Vtp5 + + + + + + + +
Mouse Adj. Only + + + + + + + +
Serum from one mouse used from each of the three groups shown; − no
growth; + growth
Table 4 Mice immunized with rVtp are protected from infection
by tick bite only when challenged with Borrelia hermsii producing
the same Vtp antigenic type
Challenge strain Vaccine Type No. Infected / No. Total
B. hermsii DAH Adjuvant Only 5/5
rVtp DAH 0/5*
rVtp LAK-3 5/5
B. hermsii LAK-3 Adjuvant Only 5/5
rVtp DAH 5/5**
rVtp LAK-3 0/5*
*Significantly different, Fisher’s exact test, p = 0.0003
**One mouse infected during second challenge
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Fig. 4 Immunoblot analysis of the serological responses in mice following immunization and challenge by tick bite. Whole-cell lysates of B.
hermsii DAH (panels a-c) and B. hermsii LAK-3 (panels d-f) were tested with individual mouse serum samples (M1-M5) from each of the 6
groups of mice immunized with rVtp Type 5, rVtp Type 6, or only the adjuvant. Mice challenged with the strain producing the same Vtp as
the vaccine were protected from infection, and showed no expansion of antibodies after challenge other than to the vaccine (the ~20 kDa
protein) (panels b and f). Mice immunized with the heterologous rVtp (panels c and e) or only the adjuvant (panels a and d) became infected
and showed an expanded antibody response after challenge, although the response was weaker in some animals (panel c). One mouse in the
LAK-3 homologous challenge group (panel f) died before the final serum samples were collected. * indicates the mouse that was infected
from the second challenge. (−) shows serum samples from non-immunized, uninfected mice. Molecular mass standards are shown in kDa
Fig. 5 Borrelia hermsii LAK-3 in a tick salivary gland following tick feeding on an immunized mouse (a) and a control mouse receiving only
the adjuvant (b). IFA stain with Vtp Type 5 specific monoclonal antibody H3548 (a) and a rabbit polyclonal anti-Vtp antibody (b). Scale bars
represent 20 μm
Krajacich et al. Parasites & Vectors  (2015) 8:546 Page 9 of 14
Discussion and conclusions
Due to the ability of relapsing fever spirochetes to evade
the host’s humoral immune response through varying
the antigenic composition of their major outer surface
proteins, the immunological responses to infection have
received much attention [37, 39–42]. In spite of this, lit-
tle effort has focused on vaccines for these infections or
developing experimental strategies for testing such appli-
cations in the laboratory. This is in stark contrast to ef-
forts devoted to developing a vaccine for Lyme disease
[43, 44], which is another tick-transmitted zoonotic spi-
rochetosis [45–47]. The lack of interest in developing a
vaccine for tick-borne relapsing fever has likely been
due, in part, to the complex and ephemeral nature of
the relapsing fever spirochete’s changing antigenic sur-
face [37, 48], which has been viewed as a major obstacle
toward the development of a vaccine [49].
Interest in vaccines for Lyme disease arose soon after
the discovery of the cause of this illness was reported
[45]. Johnson and colleagues first demonstrated that
hamsters could be passively and actively immunized to
protect these animals from infection when challenged by
needle inoculation with culture-derived B. burgdorferi
[50, 51]. Active immunity in these animals was produced
with a killed, lyophilized whole-cell spirochete prepar-
ation [50]. This “bacterin” whole-cell vaccine was soon
developed into a commercial vaccine for dogs, which is
still in use today [43, 52].
Early studies of the protein composition of Lyme dis-
ease spirochetes identified a major outer surface pro-
tein (Osp) of approximately 31,000 MW [53], which
was subsequently named OspA [54]. Several studies
demonstrated that both monoclonal antibodies and
monospecific polyclonal immune serum produced to
OspA passively protected SCID and immunocompetent
mice from clinical disease and infection with B. burg-
dorferi [33, 34, 55]. Fikrig and coworkers demonstrated
that active immunization of immunocompetent mice
with purified recombinant OspA produced a protective
antibody response [33], results which were confirmed
by other investigators [26, 56]. These corroborating re-
sults included the use of European strains of the spiro-
chete and challenge with infected ticks [36, 57]. The
mechanism of protection for anti-OspA antibodies was
based on the borreliacidal activity of the immune serum
when imbibed by infected ticks when they fed. The
protein-specific immune serum killed the OspA-
producing borrelia in the midgut of the ticks prior to
the spirochetes’ dissemination and transmission via the
salivary glands [35, 58].
A second major outer surface protein to receive much
attention while characterizing these spirochetes was a
dominant 22,000 MW, immunogenic protein first named
pC [59], and later renamed OspC [60]. Numerous
studies demonstrated that both passive and active im-
munizations involving specific immune serum or this
protein conferred protection when the immunized ani-
mals were challenged by either needle inoculation or by
the bite of infected ticks [25, 26, 56, 61, 62], however,
protection was strain-specific [24, 56]. The specificity for
protection was based on the amino acid composition of
OspC, which is polymorphic among B. burgdorferi popu-
lations [29, 63–69]. Many serotypes of OspC of B.
burgdorferi sensu lato have been described, with amino
acid sequences within each type being identical or
nearly so, while sequences between different types
share only 62–80 % identity [29, 63, 66]. Thus vaccin-
ation with OspC is only protective when the immu-
nized host is challenged with spirochetes that produce
the same OspC serotype, which is what we demon-
strate here with our Vtp vaccines for B. hermsii.
B. hermsii Vtp and B. burgdorferi OspC are ortholo-
gous proteins [20, 22, 70] and essential for mammalian
infection when these spirochetes are transmitted by
tick bite [21, 27, 71]. While OspC stimulates an early
antibody response in the majority of Lyme disease
patients [72], the humoral immune response to Vtp in
patients infected with B. hermsii has not been
evaluated. After transmission by tick bite, B. hermsii
switches off Vtp, producing instead a bloodstream
Vmp [18]. Yet the polymorphism of Vtp, as with OspC,
suggests that the sequence diversity is driven and bal-
anced by immune pressure from the natural vertebrate
host populations [29, 73].
Our interest in pursuing an experimental Vtp vaccine
was stimulated in part by 1) the efficacy of the OspC
vaccines for B. burgdorferi when tested in homologous
challenges, 2) our previous findings that B. hermsii pro-
duces Vtp and not one of the many bloodstream Vmps
during transmission by tick bite, and 3) by our initial ob-
servations presented here that immune serum produced
in a rabbit to gel-excised Vtp agglutinated and killed
Vtp-producing B. hermsii in vitro. Early investigations
demonstrated that immune serum made to several spe-
cies of relapsing fever spirochetes agglutinated those
cells to which the antibody-containing sera were pro-
duced [74]. Studies with B. hermsii showed the ability of
various immune sera to agglutinate, immobilize, or kill
spirochetes [75–78]. Most relevant to our agglutination
results was the demonstration that the anti-Vtp specific
monoclonal antibody H4825 [75] agglutinated B. hermsii
cells producing Vtp [77]. Also, two IgM monoclonal
antibodies produced to serotype 7 B. hermsii cells agglu-
tinated spirochetes and inhibited their growth in vitro
[76]. Mouse ascetic fluid containing IgG antibodies to an
unidentified B. hermsii surface protein of approximately
22 kDa (possibly Vtp) also inhibited growth and killed
spirochetes [79].
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In addition to causing agglutination and inhibiting
spirochete growth, immune sera may passively protect
animals from infection with B. hermsii [76, 80] and other
tick-borne species of spirochetes such as Borrelia dutto-
nii [81, 82]. Stoenner and colleagues tested a serotype 7-
specific polyclonal antibody to passively protect mice
from infection with B. hermsii serotype 7 cells [80].
When the recipient mice were inoculated with an in
vitro culture of serotype 7 cells that also contained small
numbers of variant spirochetes, only the variants grew
out; no serotype 7 cells were detected in the mice.
Barbour and Bundoc also showed that mice were pro-
tected from infection with B. hermsii serotype 7 cells
when passively immunized with anti-serotype 7 IgM
monoclonal antibodies [76], yet active immunization of
mice with purified recombinant Vlp7 protein failed to
protect mice from infection when challenged with sero-
type 7 spirochetes. In fact, while many studies have re-
ported that infections with relapsing fever spirochetes
produce some level of immunity and protection from re-
infection [74, 83–85], we are unaware of any studies that
demonstrate protection to infection produced by active
immunization with a single protein or subunit vaccine
for relapsing fever spirochetes.
Lyme disease vaccines have also targeted white-footed
mice (Peromyscus leucopus), a primary reservoir in the
wild, to break the transmission cycle and thereby reduce
the risk of infection to humans [86, 87]. The notion of
reducing the prevalence of O. hermsi ticks infected with
B. hermsii in the wild by immunizing the vertebrate
hosts with a Vtp-based oral vaccine is intriguing but
fraught with potential difficulties. First, the white-footed
mice need to be protected from infection with B. burg-
dorferi only when the new generation of infected I. sca-
pularis nymphs feeds on them. Unfed larvae, which feed
on white-footed mice too but are not infected transova-
rially [88], and adult ticks that feed on much larger
mammals like deer [47], play no direct role in the chain
of infection [89]. In striking contrast, every active
stage of O. hermsi has the potential to transmit B.
hermsii when they feed on their hosts, primarily squir-
rels and chipmunks (Tamiasciurus spp and Tamias
spp) [90, 91]. Larvae may become infected transova-
rially [92, 93], although the frequency of this event
needs further study. The three or occasionally four
nymphal stages are all competent vectors, as are the
adults, which can feed and transmit spirochetes re-
peatedly [94] (unpublished results).
In the laboratory, white-footed mice infected with B.
burgdorferi and subsequently vaccinated orally with
OspA reduce the prevalence of infected I. scapularis
nymphs that fed on them as larvae [95]. When the unin-
fected larvae ingest anti-OspA immune serum with the
spirochetes that upregulate OspA soon after their
acquisition [96, 97], the spirochetes are killed in the
tick’s midgut [35]. The potential for simultaneous acqui-
sition of spirochetes and immune serum by ticks feeding
on vaccinated mice in the wild is possible because
white-footed mice, once infected, remain so for life.
However, the duration of infection of B. hermsii in mam-
mals such as chipmunks is transient in comparison and
lasts only a few weeks [98]. While immunization of chip-
munks and squirrels in the field should protect these an-
imals from infection with B. hermsii producing the
homologous Vtp when fed upon by infected ticks, the
immune serum would likely have no impact on the
prevalence of infected ticks. If O. hermsi ticks were to
acquire spirochetes from an immunized host, the spiro-
chetes would not be producing Vtp at the time of acqui-
sition [21], and therefore not be susceptible to killing by
the immune serum. Also, given that B. hermsii persists
in the tick’s salivary glands rather than the midgut as
does B. burgorferi, those spirochetes producing Vtp in
the salivary glands may not be subjected to immune
clearance when ticks ingest blood containing anti-Vtp
antibodies. This notion was supported by our observa-
tions in which infected O. hermsi ticks that fed on mice
immunized with the homologous Vtp remained infected,
retained Vtp-producing spirochetes in their salivary
glands, and subsequently infected naïve mice. These ob-
servations, and the rapidity at which relapsing fever spi-
rochetes may be transmitted after tick attachment (less
than 1 min) [99, 100], indicate that these Vtp vaccines
result in the killing of spirochetes in the immunized host
rather than blocking transmission by killing spirochetes
in ticks prior to transmission.
If oral immunization with Vtp were to produce a pro-
tective immune response (yet to be determined), a field
application providing the best chance to immunize a sig-
nificant proportion of wild hosts might be an island
community that has a small and isolated geographic
area, a reduced diversity of host species, and a limited
diversity of Vtp types in the B. hermsii population. Such
potential target areas exist on islands in Flathead Lake of
western Montana [101], where tick-borne relapsing fever
caused by B. hermsii is endemic [5, 30]. Here, baited sta-
tions similar to those developed for the control of fleas
during epizootics of plague [102] could be applied to at-
tract pine squirrels (no chipmunks live on the islands) to
provide a multivalent vaccine, such as proposed for a
Lyme disease OspC vaccine [103], which contains all the
Vtp types present on the island. Various approved acari-
cides in a dust formulation could be added to these bait
stations, so the squirrels would contaminate their hair
while eating the vaccine-impregnated bait, and carry the
toxic dusts to their nests to better target the ticks. A
persistent, multiannual application could reduce the
population of infected ticks and thereby lessen the risk
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of human infection for people visiting these islands.
Current efforts to identify salivary gland antigens and
midgut membrane proteins of Ornithodoros species of
ticks as potential anti-tick vaccines might also hold
promise in the future to help reduce targeted tick popu-
lations in discrete natural foci of infection [104].
Our development of the experimental vaccine pre-
sented here was based on knowledge of how B. hermsii
adapts and changes its outer surface when persistently
infecting the tick vector’s salivary glands [18, 21]. Such
phenotypic switches may occur in other species, such as
B. duttonii and Borrelia recurrentis, which cycle directly
between human hosts with their tick and louse vectors,
respectively, without involvement of wild animal reser-
voirs. Future investigations delving into the mechanisms
of how these species alter their outer surface while
infecting their arthropod vectors could provide new
strategies for protection in highly endemic areas.
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